Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
uniQure N.V. is a biotechnology company focused on the discovery, development, and commercialization of gene therapies based on adeno-associated viral (AAV) vectors. The company operates within the biotechnology and gene therapy industries, targeting severe genetic and neurological diseases with high unmet medical need. Its core competency lies in developing one-time, potentially curative treatments by delivering functional genes to patients.
The company’s primary value drivers include its proprietary AAV-based gene therapy platform and a pipeline led by therapies for hemophilia B and Huntington’s disease. uniQure is uniquely positioned as one of the first gene therapy companies to achieve regulatory approval for a systemically delivered AAV gene therapy. The company was founded in 1998 in the Netherlands as Amsterdam Molecular Therapeutics, later rebranded as uniQure, and became publicly listed on NASDAQ in 2014.
Business Operations
uniQure operates as a single-reportable operating segment focused on gene therapy research, clinical development, and selective commercialization through partnerships. Revenue generation is primarily derived from collaboration payments, license fees, and royalties, most notably from its hemophilia B gene therapy, HEMGENIX, which is commercialized by CSL Behring under a global licensing and commercialization agreement.
The company controls a proprietary AAV gene therapy technology platform and maintains in-house capabilities for process development and manufacturing. Its operations include wholly owned subsidiaries supporting R&D and manufacturing activities, particularly in the United States. uniQure does not maintain large-scale commercial infrastructure, instead leveraging strategic partnerships for late-stage development and commercialization.
Strategic Position & Investments
Strategically, uniQure is focused on advancing a focused pipeline of differentiated gene therapies while managing capital through partnerships and disciplined investment. A key strategic milestone was the out-licensing of HEMGENIX to CSL Behring, which provided upfront payments and established a long-term royalty stream. This transaction significantly reduced commercialization risk while enabling continued participation in the product’s upside.
The company’s primary growth initiative is the development of AMT-130, an investigational gene therapy for Huntington’s disease, which is currently in clinical development. uniQure continues to invest in next-generation AAV vector technology and manufacturing innovation to improve durability, safety, and scalability. No material acquisitions have been disclosed in recent periods; investment activity has focused on internal R&D and platform enhancement.
Geographic Footprint
uniQure is headquartered in Amsterdam, the Netherlands, and maintains a significant operational presence in the United States, particularly in Massachusetts, where its principal clinical development and manufacturing activities are based. These locations support global research, development, and regulatory operations.
The company’s market and clinical footprint is international, with clinical trials conducted across North America and Europe, and commercial exposure extending globally through its partnership with CSL Behring. While uniQure does not operate a broad international sales organization, its therapies are positioned for global reach via partners and regulatory approvals in multiple regions.
Leadership & Governance
uniQure is led by an executive team with experience in biotechnology, rare diseases, and gene therapy development. The leadership emphasizes scientific rigor, capital discipline, and strategic partnerships as central elements of the company’s long-term vision.
Key executives include:
- Matthew C. Kapusta – Chief Executive Officer
- Ryan M. Gilbert – Chief Financial Officer
- Walther Van Deventer – Chief Medical Officer
- Raymond J. Bartus – Senior Vice President, Research
- Pierre Caloz – Senior Vice President, Technical Operations
The company is governed by a board of directors with expertise in life sciences, finance, and corporate governance, supporting its focus on long-term value creation and responsible clinical development.